Teva Adds To Biosimilars Capabilities Through Partnership With Lonza
Executive Summary
Even as big pharma continues to express interest in developing follow-on biologics, Teva has taken a step toward solidifying a leadership position in the space. The world's largest generic company announced a tie-up Jan. 20 with the privately held Swiss contract manufacturing group Lonza
You may also be interested in...
Lonza Forms JV With Shanghai Fosun To Tap Chinese Generics Market
Swiss firm Lonza Group AG, a global supplier of active pharmaceutical ingredients has announced a joint venture with Shanghai Fosun Pharmaceutical. The 50/50 JV will develop and launch a portfolio of generic products in China
On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era
The health care reform legislation signed into law by President Obama March 23 paves the way for the launch of biosimilar drugs in the U.S., action that could save the country's health care system billions of dollars, while presenting both challenges and opportunities for the drug industry
On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era
The health care reform legislation signed into law by President Obama March 23 paves the way for the launch of biosimilar drugs in the U.S., action that could save the country's health care system billions of dollars, while presenting both challenges and opportunities for the drug industry